Welcome to AMLdb: A database for Acute Myeloid Leukemia!

Acute myeloid leukemia (AML) is a rare cancer usually detected at an advanced stage. It's a disease of immature blood cells. Instead of developing into mature blood cells with finite lifespan, cells with compromised DNA or compromised regulation of DNA continue to divide. Eventually, these diseased cells take over and cause devastating effects on the body. Most patients survive just a few weeks or months after diagnosis. Understanding how AML occurs is difficult because the disease develops silently for many years before patients suddenly have severe symptoms. Therefore, studying AML is challenging.
Taking these challenges into account, we developed AMLdb as a one-stop resource for anyone seeking information on AML. Our database provides comprehensive information on transcriptional and epigenetic dynamics in AML with special emphasis on mutations and drug sensitivity that can help to understand the etiology of the disease, identify and validate biomarkers, classify patients and predict personalized treatment regimens and outcomes. The data has been collected and curated manually from literature as well as repositories and databases like GEO, DepMap, cBioPortal, GDSC and COSMIC.
Through an integrated analysis of the collected datasets, AMLdb has unveiled novel gene targets for AML, including CBFB, ENO1, IMPDH2, SEPHS2, and MYH9, paving the way for innovative therapeutic interventions.